FADROZOLE HYDROCHLORIDE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C14H13N3.ClH
Molecular Weight	259.734
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

Cl.N#CC1=CC=C(C=C1)C2CCCC3=CN=CN23

InChI

InChIKey=UKCVAQGKEOJTSR-UHFFFAOYSA-N

InChI=1S/C14H13N3.ClH/c15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14;/h4-7,9-10,14H,1-3H2;1H

HIDE SMILES / InChI

Molecular Formula	C14H13N3
Molecular Weight	223.2731
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Fadrozole (CGS 16949A) is a tetrahydroimidazole-pyridine derivative is a non-steroidal inhibitor of aromatase. In the third phase of clinical trials it was shown, that this drug has good therapeutic effect as a second-line treatment in postmenopausal women with metastatic breast cancer.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cytochrome P450 19A1 39	Inhibitor 8,297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Breast cancer 434	Primary		Phase III 656	Unknown

C_max

Value	Dose	Analyte	Population
32.3 ng/mL	12 mg single, oral	FADROZOLE plasma	Homo sapiens
27.4 ng/mL	12 mg single, oral	FADROZOLE plasma	Homo sapiens
1.5 ng/mL	0.3 mg 2 times / day multiple, oral	FADROZOLE plasma	Homo sapiens
1.5 ng/mL	1 mg 2 times / day multiple, oral	FADROZOLE plasma	Homo sapiens
1.5 ng/mL	2 mg 2 times / day multiple, oral	FADROZOLE plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
336 ng × h/mL	12 mg single, oral	FADROZOLE plasma	Homo sapiens
306 ng × h/mL	12 mg single, oral	FADROZOLE plasma	Homo sapiens
10.7 ng × h/mL	0.3 mg 2 times / day multiple, oral	FADROZOLE plasma	Homo sapiens
10.5 ng × h/mL	1 mg 2 times / day multiple, oral	FADROZOLE plasma	Homo sapiens
10.7 ng × h/mL	2 mg 2 times / day multiple, oral	FADROZOLE plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.8 h	12 mg single, oral		FADROZOLE plasma	Homo sapiens
2.5 h	12 mg single, oral		FADROZOLE plasma	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
12 mg single, oral Highest studied dose	healthy, ADULT
2 mg 2 times / day multiple, oral Highest studied dose	unhealthy, ADULT	Disc. AE: Depression, Lethargy...
1 mg 2 times / day multiple, oral Studied dose	unhealthy, ADULT	Disc. AE: Weakness, Dizziness...

Showing 1 to 3 of 3 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Depression	grade 3, 3.6% Disc. AE	2 mg 2 times / day multiple, oral Highest studied dose	unhealthy, ADULT
Lethargy	grade 3, 3.6% Disc. AE	2 mg 2 times / day multiple, oral Highest studied dose	unhealthy, ADULT
Dizziness	0.95% Disc. AE	1 mg 2 times / day multiple, oral Studied dose	unhealthy, ADULT
Weakness	0.95% Disc. AE	1 mg 2 times / day multiple, oral Studied dose	unhealthy, ADULT

Showing 1 to 4 of 4 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
Are differences in the available aromatase inhibitors and inactivators significant?	2001 Dec	11916226
Masculinized sexual partner preference in female zebra finches with sex-reversed gonads.	2001 Feb	11161880
Enantioselectivity of some 1-[(benzofuran-2-yl) phenylmethyl] imidazoles as aromatase (P450AROM) inhibitors.	2001 Nov	11916146
Estrogen stimulates brain-derived neurotrophic factor expression in embryonic mouse midbrain neurons through a membrane-mediated and calcium-dependent mechanism.	2001 Oct 15	11592117
Testosterone promotes paternal behaviour in a monogamous mammal via conversion to oestrogen.	2002 Apr 22	11958714

Showing 1 to 5 of 30 entries

Previous1 2 3 4 5 6Next

Patents

Sample Use Guides

In Vivo Use Guide

0.5, 1.0 or 2.0 mg orally b.d.

Route of Administration: Oral

In Vitro Use Guide

CGS-16949A (fadrozole) blocked aromatase by 50% in human breast cancer homogenates, live breast cancer cells, human placental microsomes and porcine ovarian microsomes at concentrations of 0.008 to 0.02 microM

Substance Class	Chemical
Record UNII	H0Q44H4ECQ
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

FADROZOLE HYDROCHLORIDE

Official Name

English

FADROZOLE HYDROCHLORIDE [MI]

Common Name

English

FADROZOLE HYDROCHLORIDE [USAN]

Common Name

English

Fadrozole hydrochloride [WHO-DD]

Common Name

English

CGS 16949A

Code

English

Showing 1 to 5 of 11 entries

Previous1 2 3Next

Show entries

Classification Tree

Code System

Code

Aromatase Inhibitor

NCI_THESAURUS

C2018

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Code System

Code

Type

Description

ChEMBL

CHEMBL9298

PRIMARY

PUBCHEM

59694

PRIMARY

FDA UNII

H0Q44H4ECQ

PRIMARY

SMS_ID

100000078562

PRIMARY

USAN

BB-36

PRIMARY

Showing 1 to 5 of 10 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					O5207G4XQ9

FADROZOLE HYDROCHLORIDE HEMIHYDRATE

SALT/SOLVATE -> PARENT


					H3988M64PU

FADROZOLE

PARENT -> SALT/SOLVATE


					98FJW82E98

FADROZOLE HYDROCHLORIDE, (S)-

ENANTIOMER -> RACEMATE


					O5207G4XQ9

FADROZOLE HYDROCHLORIDE HEMIHYDRATE

SOLVATE->ANHYDROUS

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Related Record

Type

Details


					H3988M64PU

FADROZOLE

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Doses

AEs

PubMed

Patents

Sample Use Guides

C_max

T_1/2